Press Releases :: Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

Aug 2, 2023

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

Jul 19, 2023

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

Jul 11, 2023

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

Jul 3, 2023

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

Jun 13, 2023

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

May 22, 2023

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 19, 2023

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

May 11, 2023

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

May 4, 2023

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

Mar 29, 2023

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

rss_feed News RSS